# A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

> **NCT06097663** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Coronary Heart Disease
- Clonal Hematopoiesis of Indeterminate Potential (CHIP)

## Interventions

- **DRUG:** MAS825
- **DRUG:** MAS825 Placebo
- **DRUG:** DFV890
- **DRUG:** DFV890 placebo

## Key facts

- **NCT ID:** NCT06097663
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-15
- **Primary completion:** 2024-10-27
- **Final completion:** 2024-11-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097663, "A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06097663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*